Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abuse-Deterrent Opioids Effectiveness, Value To Get ICER Review

Executive Summary

Pending arrival of several new products prompts evaluation of class, ICER CSO Dan Ollendorf explains; availability of both abuse-deterrent and non-abuse-deterrent drugs among challenging issues.

You may also be interested in...



Abuse-Deterrent Opioids: FDA Advocates Joint Brand-Generic Development Plan

Despite ‘tension’ between two industries over what is required to show generic is no less abuse-deterrent than innovator opioid, FDA’s Throckmorton suggests they come up with single approach to product development.

Abuse-Deterrent Opioids: FDA Advocates Joint Brand-Generic Development Plan

Despite ‘tension’ between two industries over what is required to show generic is no less abuse-deterrent than innovator opioid, FDA’s Throckmorton suggests they come up with single approach to product development.

Value Vs. Values: ICER’s Review Of Opioid Abuse-Deterrent Formulations

The Institute for Clinical & Economic Review is setting an appropriately broad scope in its review of the abuse-deterrent opioid class. But the project opens up a much larger question of how broadly to define value – and how to weigh non-economic values – in cost-effectiveness reviews.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel